A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating ...
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating ...
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\] by mouth \[p.o.\]) compared to dupilumab (600 mg l...
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU)....
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT ...
Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended...
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days. All subjects wil...
Top Cities for Chronic Spontaneous Urticaria Clinical Trials
Chronic Spontaneous Urticaria clinical trials are recruiting across 44 cities. Here are the cities with the most active studies:
About Chronic Spontaneous Urticaria
Chronic spontaneous urticaria involves the recurrence of hives and/or angioedema for more than six weeks without an identifiable external trigger. It significantly impacts quality of life. Treatment includes second-generation antihistamines and biologics like omalizumab.
Clinical trials are advancing new treatments for chronic spontaneous urticaria. Currently, 7 studies are recruiting a combined 2,650 participants across the United States. Research is being conducted by 6 organizations including Celldex Therapeutics, Novartis Pharmaceuticals, Evommune, Inc. and 3 others.
2026 Chronic Spontaneous Urticaria Research Landscape
As of March 2026, the chronic spontaneous urticaria clinical trial landscape includes 7 actively recruiting studies across 44 cities in the United States. These studies are collectively seeking 2,650 participants, with an average enrollment target of 379 per study.
Research is being led by 6 different organizations, including Celldex Therapeutics, Novartis Pharmaceuticals, Evommune, Inc., Blueprint Medicines Corporation, Jasper Therapeutics, Inc., and 1 others.
Geographically, chronic spontaneous urticaria trials are most concentrated in Los Angeles, California (7 trials); Birmingham, Alabama (4 trials); San Diego, California (4 trials); Tampa, Florida (4 trials); Scottsdale, Arizona (3 trials) and 7 other cities.
Featured Chronic Spontaneous Urticaria Studies
Highlighted recruiting studies for chronic spontaneous urticaria, selected by enrollment size and research scope.
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\] by mouth \[p.o.\]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when administered as an add-on treatment to second generation H1-antihi...
Frequently Asked Questions About Chronic Spontaneous Urticaria Clinical Trials
Are there chronic spontaneous urticaria clinical trials near me?
Yes, there are 7 chronic spontaneous urticaria clinical trials currently recruiting across 44+ cities in the United States, including Los Angeles, California; Birmingham, Alabama; San Diego, California. Browse the studies above to find one at a location convenient for you.
How do I join a chronic spontaneous urticaria clinical trial?
To join a chronic spontaneous urticaria clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are chronic spontaneous urticaria clinical trials free?
Yes, participation in chronic spontaneous urticaria clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of chronic spontaneous urticaria treatments are being studied?
Current chronic spontaneous urticaria clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 6 research organizations.
Is it safe to participate in chronic spontaneous urticaria clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov